Relapse is driven by the Darwinian evolution of sub‐clones present at initial diagnosis associated with drug resistance (NT5C2 and TP53 mutations) and re‐iterative mutation of known key T‐ALL drivers, including NOTCH1. Here, TP53 is linked to acute lymphoblastic leukemia.